Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.36 |
| ▸ | ESR1 | P03372 | 2/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | KCNN4 | O15554 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2789075 | 0.78 | TSHR (0.50) | TSHRTAAR1RIPK1 | |
| SCHEMBL29716732 | 0.78 | MAPK1 (0.44) | TSHRMAPK1ALDH1A1TAAR1ALOX15 | |
| SCHEMBL1059023 | 0.76 | MAPK1 (0.42) | MAPK1ALDH1A1TAAR1ALOX15RIPK1 | |
| SCHEMBL1059025 | 0.76 | MAPK1 (0.42) | MAPK1ALDH1A1TAAR1ALOX15RIPK1 | |
| SCHEMBL28952946 | 0.76 | TSHR (0.48) | TSHRALDH1A1TAAR1CNR1CNR2 | |
| Phosphine SCHEMBL23160875 | 0.74 | MAPK1 (0.41) | MAPK1ALDH1A1TAAR1ALOX15RIPK1 | |
| SCHEMBL1885792 | 0.74 | TSHR (0.52) | TSHRTAAR1RIPK1 | |
| SCHEMBL10634567 | 0.74 | RIPK1 (0.42) | MAPK1ALDH1A1TAAR1ALOX15RIPK1 | |
| SCHEMBL5459793 | 0.74 | TSHR (0.46) | TSHRALDH1A1TAAR1CNR1CNR2 | |
| SCHEMBL4331799 | 0.74 | TSHR (0.46) | TSHRRIPK1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12624355-B2 | Double-stranded oligonucleotide, composition and conjugate comprising double-stranded oligonucleotide, preparation method thereof and use thereof | Suzhou Ribo Life Science Co., Ltd. (CN) | 2026-05-12 | — | — | US | disclosed |
| US-12428642-B2 | Nucleic acid, composition and conjugate comprising the same, preparation method and use thereof | Suzhou Ribo Life Science Co., Ltd. (CN) | 2025-09-30 | — | — | US | disclosed |
| US-12274752-B2 | Nucleic acid, composition and conjugate containing same, preparation method, and use thereof | Suzhou Ribo Life Science Co., Ltd. (CN) | 2025-04-15 | — | — | US | disclosed |
| EP-4527459-A2 | NUCLEIC ACID, COMPOSITION AND CONJUGATE CONTAINING NUCLEIC ACID, PREPARATION METHOD THEREFOR AND USE THEREOF | Suzhou Ribo Life Science Co., Ltd. (CN) | 2025-03-26 | — | — | EP | disclosed |
| EP-3732185-B1 | CONJUGATES AND PREPARATION AND USE THEREOF | SUZHOU RIBO LIFE SCIENCE CO LTD (CN) | 2025-02-26 | — | — | EP | disclosed |
| EP-3719128-B1 | DOUBLE-STRANDED OLIGONUCLEOTIDE, COMPOSITION AND CONJUGATE COMPRISING DOUBLE-STRANDED OLIGONUCLEOTIDE, PREPARATION METHOD THEREFOR AND USE THEREOF | SUZHOU RIBO LIFE SCIENCE CO LTD (CN) | 2025-01-15 | — | — | EP | disclosed |
| EP-3719125-B1 | NUCLEIC ACID, COMPOSITION AND CONJUGATE CONTAINING SAME, AND PREPARATION METHOD AND USE | SUZHOU RIBO LIFE SCIENCE CO LTD (CN) | 2025-01-08 | — | — | EP | disclosed |
| EP-3719126-B1 | NUCLEIC ACID, COMPOSITION AND CONJUGATE CONTAINING NUCLEIC ACID, PREPARATION METHOD THEREFOR AND USE THEREOF | SUZHOU RIBO LIFE SCIENCE CO LTD (CN) | 2025-01-01 | — | — | EP | disclosed |
| US-20240382514-A1 | NUCLEIC ACID, COMPOSITION AND CONJUGATE CONTAINING SAME, AND PREPARATION METHOD AND USE THEREOF | Suzhou Ribo Life Science Co., Ltd. (CN) | 2024-11-21 | — | — | US | disclosed |
| EP-4455285-A2 | NUCLEIC ACID, COMPOSITION AND CONJUGATE COMPRISING THE SAME, AND PREPARATION METHOD AND USE THEREOF | Suzhou Ribo Life Science Co., Ltd. (CN) | 2024-10-30 | — | — | EP | disclosed |
| CN-111050807-A | Nucleic acid, composition containing nucleic acid, conjugate, preparation method and application | 苏州瑞博生物技术有限公司 | 2020-04-21 | — | — | CN | disclosed |
| CN-110997919-A | Double-stranded oligonucleotide, composition containing double-stranded oligonucleotide, conjugate, preparation method and application | 苏州瑞博生物技术有限公司 | 2020-04-10 | — | — | CN | disclosed |
| CN-110997917-A | Nucleic acid, composition containing nucleic acid, conjugate, preparation method and application | 苏州瑞博生物技术有限公司 | 2020-04-10 | — | — | CN | disclosed |
| CN-110959011-A | Conjugate, preparation method and application thereof | 苏州瑞博生物技术有限公司 | 2020-04-03 | — | — | CN | disclosed |
| WO-2020063198-A1 | SIRNA CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | 苏州瑞博生物技术有限公司 | 2020-04-02 | — | — | WO | disclosed |
| CN-110944675-A | Nucleic acid, composition containing nucleic acid, conjugate, preparation method and application | 苏州瑞博生物技术有限公司 | 2020-03-31 | — | — | CN | disclosed |
| CN-110945130-A | Nucleic acid, composition containing nucleic acid, conjugate, preparation method and application | 苏州瑞博生物技术有限公司 | 2020-03-31 | — | — | CN | disclosed |
| CN-110945132-A | Nucleic acid, composition containing nucleic acid, conjugate, preparation method and application | 苏州瑞博生物技术有限公司 | 2020-03-31 | — | — | CN | disclosed |
| CN-110945131-A | Nucleic acid, composition containing nucleic acid, conjugate, preparation method and application | 苏州瑞博生物技术有限公司 | 2020-03-31 | — | — | CN | disclosed |
| WO-2020038377-A1 | NUCLEIC ACID, PHARMACEUTICAL COMPOSITION AND CONJUGATE CONTAINING NUCLEIC ACID, AND USE THEREOF | 苏州瑞博生物技术有限公司 | 2020-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12624355-B2 | Double-stranded oligonucleotide, composition and conjugate comprising double-stranded oligonucleotide, preparation method thereof and use thereof | RNGTT, RNMT, NSUN2 | TSHR 1045/4885MAPK1 3750/4885ALDH1A1 4357/4885 |
| US-12274752-B2 | Nucleic acid, composition and conjugate containing same, preparation method, and use thereof | APOB, C1QBP, APOL1 | TSHR 3909/4885MAPK1 3734/4885ALDH1A1 3395/4885 |
| US-20240382514-A1 | NUCLEIC ACID, COMPOSITION AND CONJUGATE CONTAINING SAME, AND PREPARATION METHOD AND USE THEREOF | RNGTT, NSUN2, ADAR | TSHR 4012/4885MAPK1 3374/4885ALDH1A1 3387/4885 |
| US-12428642-B2 | Nucleic acid, composition and conjugate comprising the same, preparation method and use thereof | TEK, TIE1, IGF2BP3 | TSHR 3761/4885MAPK1 3910/4885ALDH1A1 3395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.